MedDataX Logo

Effectiveness Study of the Ivivi SofPulse for Pain Amelioration in Adults With Mild to Moderate Knee Osteoarthritis

NCT ID: NCT01457742

Last Updated: 2012-07-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effectiveness of non-thermal Pulsed Radio Frequency (PRF) treatment with the Ivivi SofPulse for amelioration of knee pain in patients with mild to moderate Osteoarthritis and to determine the duration of clinical benefit following discontinuation of treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective, double-blind, randomized, sham-controlled clinical trial will investigate the effectiveness of PRF using the Ivivi SofPulse on knee pain severity in adults with mild to moderate knee OA. Potential subjects will complete questions related to medical history, inclusion / exclusion criteria, and OA symptom severity. Knee radiographs will be evaluated by the Principal Investigator (PI) or co-investigator for determination of knee OA severity based on the Kellgren/Lawrence criteria. Eligible subjects will enter a 1-week run-in period. After successful completion of the run-in period, subjects will be randomized to PRF treatment twice a day (Active) or sham treatment twice a day (Sham). All subjects will be followed for 4 weeks for purposes of the primary endpoint evaluation. Thereafter, the subjects initially allocated to Active will be equally allocated to Active or Sham and will be followed through 26 or 8 weeks, respectively. The subjects originally assigned to Sham will maintain this treatment regimen through 26 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulsed Radio Frequency (PRF)

Group Type ACTIVE_COMPARATOR

Ivivi SofPulse

Intervention Type DEVICE

15 minute Pulsed Radio Frequency (PRF) treatment twice per day

Sham

Use of Sham device for 15 minutes simulated treatment twice per day

Group Type SHAM_COMPARATOR

Ivivi SofPulse

Intervention Type DEVICE

15 minute simulated treatment using Sham Device twice per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivivi SofPulse

15 minute Pulsed Radio Frequency (PRF) treatment twice per day

Intervention Type DEVICE

Ivivi SofPulse

15 minute simulated treatment using Sham Device twice per day

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 40 to 80 years
* Bilateral weight-bearing anteroposterior x-ray of each knee taken within the last 12 months and radiographs submitted to the Principal Investigator for evaluation
* Radiographic evidence of mild to moderate (Kellgren/Lawrence grade 2 or 3) OA in at least one knee based on a weight-bearing anteroposterior x-ray taken within the last 12 months
* Self-reported persistent knee pain severity of 4.0 to 8.0 cm on a 10 cm VAS for most days in the previous 2 months in at least one knee, with grade 2 or 3 OA
* Able to read and complete English-language surveys
* Daily access to the internet
* Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects
* Consent to the study and willing to comply with study methods

Exclusion Criteria

* Subjects who have any implanted metallic leads, wires, or systems (e.g. pacemaker, implantable cardioverterdefibrillator)
* Self-reported persistent knee pain severity \> 8.0 cm on a 10 cm VAS in either knee for most days in the previous 2 months
* Radiographic evidence of severe (Kellgren/Lawrence grade 4) OA in either knee based on a weight-bearing anteroposterior x-ray taken within the last 12 months
* Self-reported diagnosis of autoimmune or inflammatory arthritis (e.g. Rheumatoid Arthritis, Lupus, etc.)
* More than 8 days of narcotic pain medication in the last 30 days
* Joint surgery, tidal lavage, or arthroscopy of either knee in the past 6 months
* Intra-articular corticosteroid or hyaluronic acid injections of either knee in the past 6 months
* Oral prednisone use in the past 30 days
* Participation in any clinical trial in the past 30 days
* Knee OA associated with worker's compensation or accident litigation
* Regular use of a walker or wheelchair
* Vulnerable populations including prisoners and nursing home residents
* Anticipated move away from immediate area in next 6 months
* Any medical condition that, in the opinion of the investigator, may compromise patient safety or confound the assessment of treatment effectiveness

After 1-week Run-in Period

* Daily average of "current" knee pain severity \< 4.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in both knees
* Daily average of "current" knee pain severity \> 8.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in either knee
* Daily average of "current" knee pain severity of 4.0 to 8.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in any knee with Kellgren/Lawrence grades of 0 or 1 in the same knees
* Narcotic use of more than 2 days during the 1-week runin period
* Noncompliance with online symptom reporting requirements
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amp Orthopedics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nancy Lane, M.D.

Role: PRINCIPAL_INVESTIGATOR

Mytrus, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mytrus, Inc.

San Francisco, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mytrus.com

website for Mytrus

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ivivi-OAPain-001

Identifier Type: -

Identifier Source: org_study_id